Amylin names new senior vice president of sales and marketing

Before joining Amylin, Mr Mihalik was vice president of global brand development diabetes and endocrine platform team leader at Eli Lilly and Company.

Mr Mihalik will oversee marketing and sales for Amylin’s two marketed products, Byetta injection and Symlin injection, as well as the launch and commercialization of exenatide once weekly, Amylin’s lead development compound. Mr Mihalik will become a member of Amylin’s executive committee.

Daniel Bradbury, president and CEO of Amylin, said: “Vince will add significant value to Amylin as we look to grow Byetta and Symlin revenue and finalize our commercial plans for exenatide once weekly. As an integral part of our executive committee, we look forward to the strategic contributions Vince will make, as well as the fresh perspective he will bring during this exciting time.”